PPT-Stroke Hyperglycemia Insulin

Network Effort SHINE Trial NIHNINDS U01 NS069498 An Overview of SHINE Contents Background Trial Overview Treatment Groups Outcomes ISPOT Ancillary Study SHINE Background Most animal stroke studies show that hyperglycemia at stroke onset leads to worse outcomes than . Pens. Prepared by: Alison . Deux. , 4. th. year pharmacy student. Background on Diabetes. More than 9 MILLION Canadians are living with diabetes or pre-diabetes. 20 more people are diagnosed every hour. Trial. Treatment Protocols. Askiel Bruno, MD, MS. Protocol PI. Agenda. General protocol for control group/ intervention group. Discussion of meals. H. ypoglycemia protocol. Pauses of study protocol. Pharmacoepidemiology and Drug Safety. 2008;(17):753-759.. So benefit of both SU/Insulin in. research studies –UKPDS, DCCT/EDIC. But adverse risk in ‘real world’ use. Link between hypoglycemia and acute cardiovascular events in type 2 diabetes. Trial. I-SPOT. Nina Gentile, MD. Hannah Reimer. I-SP T. O. I. nsights on . S. elected . P. rocoagulation markers and . O. utcomes in stroke . T. rial. I-SPOT. The . I. nsights on . S. elected . P. R. esistance and Diabetes. Alfred Martello, MD. Medical Director. The Ohio Anesthesia Group. Disclosures. No Commercial endorsements. I’m not really smart enough to give this lecture.. It’s really complicated stuff.. 1. Overview. 2. Inpatient Hyperglycemia and Poor Outcomes in Numerous Settings. Study. Patient Population. Significant Hyperglycemia-Related Outcomes. Pasquel et al, 2010. Total parenteral nutrition. Anne Marie Mattingly. Assistant Professor of Medicine. Division of Pulmonary and Critical Care. September 22, 2014. Goals of Treatment. Accurately diagnose DKA and/or HHS. Provide optimal volume resuscitation. Trial. Treatment Protocols. Askiel Bruno, MD, MS. Protocol PI. Agenda. General protocol for control group/ intervention group. Discussion of meals. H. ypoglycemia protocol. Pauses of study protocol. A Review of the Basic Science. 1. Prevalence of Hyperglycemia in Critically Ill Patients. 2. CIAH, critical illness associated hyperglycemia.. Plummer MP, et al. . Intensive Care Med. . 2014;40:973-980.. NATA Position Statement:. Management of the Athlete with Type 1 Diabetes Mellitus. Journal of Athletic Training. 2007;42(4) 536-545. Diabetes Mellitus. Type I . Chronic endocrine disorder characterized by hyperglycemia. Melissa Ashdown BSN, CDE, CPT. G. Denise Cooks, MSN, CPNP-PC, CDE, CPT. Objectives. Understand the difference between Continuous Glucose Monitors and Insulin Pumps. Describe hyperglycemia and hypoglycemia. Ups and Downs. of Blood Sugars. Attendee 1 – City TX. Glucose. Danger . values - . <. 40 . g/dl; >. 1000 . g/dl. Hyperglycemia. Brain . dehydration due to . hyperosmosis. CNS . signs (cerebral, brain stem) and seizures. Soheila. . Sadeghi. What is the diagnosis ?. What are the differences between MODY and type 1 , 2 DM ?. MODYs subtypes?. Indications for genetic testing ?. What are the Benefits of Diagnosing MODY?. What effect does glycemic control with insulin have on these complications?. None. . Insulin does not improve mortality rates/neurological outcomes after stroke. Why do we care?. Stroke is the 5. th.